Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Role for the EWS domain of EWS/FLI in binding GGAA-microsatellites required for Ewing sarcoma anchorage independent growth.

Johnson KM, Mahler NR, Saund RS, Theisen ER, Taslim C, Callender NW, Crow JC, Miller KR, Lessnick SL.

Proc Natl Acad Sci U S A. 2017 Sep 12;114(37):9870-9875. doi: 10.1073/pnas.1701872114. Epub 2017 Aug 28.

2.

Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.

Theisen ER, Pishas KI, Saund RS, Lessnick SL.

Oncotarget. 2016 Apr 5;7(14):17616-30. doi: 10.18632/oncotarget.7124. Review.

3.

Empowering people to change occupational behaviours to address critical global issues.

Ikiugu MN, Westerfield MA, Lien JM, Theisen ER, Cerny SL, Nissen RM.

Can J Occup Ther. 2015 Jun;82(3):194-204.

PMID:
26103717
4.

Reversible inhibition of lysine specific demethylase 1 is a novel anti-tumor strategy for poorly differentiated endometrial carcinoma.

Theisen ER, Gajiwala S, Bearss J, Sorna V, Sharma S, Janat-Amsbury M.

BMC Cancer. 2014 Oct 9;14:752. doi: 10.1186/1471-2407-14-752.

5.

Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.

Sankar S, Theisen ER, Bearss J, Mulvihill T, Hoffman LM, Sorna V, Beckerle MC, Sharma S, Lessnick SL.

Clin Cancer Res. 2014 Sep 1;20(17):4584-97. doi: 10.1158/1078-0432.CCR-14-0072. Epub 2014 Jun 24.

6.

High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors.

Sorna V, Theisen ER, Stephens B, Warner SL, Bearss DJ, Vankayalapati H, Sharma S.

J Med Chem. 2013 Dec 12;56(23):9496-508. doi: 10.1021/jm400870h. Epub 2013 Nov 23.

PMID:
24237195

Supplemental Content

Loading ...
Support Center